Belumosudil - Isotope Labelled Standards
References
FAQ's
References
- Campbell, Stewart; Foudoulakis, Hope; Kirk, Brian; Ram, Siya; Bartolozzi, Alessandra; Sweetnam, Paul, Pharmacokinetically Improved Compounds, WO2006105081A2, Oct 5, 2006, Surface Logix, Inc., United States
- Reddy, T. Raja; Namburi, L. A. Amarbabu; Reddy, M. B. Madhusudana, UPLC method determination and quantification of belumosudil and its impurities in the human plasma samples, Rasayan Journal of Chemistry, Volume: 17, Issue: 1, Pages: 207-214, 2024, DOI: (10.31788/rjc.2024.1718697)
Frequently Asked Questions
What are the common types of Belumosudil impurities encountered?
Common Belumosudil impurities include related substances, degradation products, and residual solvents.
Why is it essential to control Belumosudil impurities during synthesis?
Controlling Belumosudil impurities is crucial to ensure the final pharmaceutical product's safety, efficacy, and quality.
What are the storage conditions for Belumosudil to prevent impurity formation?
What are the safety measures when handling Belumosudil impurities in a laboratory?
What are the safety measures when handling Belumosudil impurities in a laboratory?
The safety measures are wearing appropriate personal protective equipment (PPE), working in a well-ventilated area, and following standard operating procedures for handling hazardous chemicals.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.